Similarly, worse survival and 5-year SR were also observed for the patients with MACC1 above the cut-off in either colon cancer (71.9 vs. 94.4 months; p < 0.001; Supplementary Figure 1B) or rectal cancers (43.8 vs. 75.0 months; p < 0.001; Supplementary Figure 1C). Here, MACC1 is linked to malignant colon neoplasm.